Previous 10 | Next 10 |
VANCOUVER, Washington, Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
VANCOUVER, Washington, Nov. 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective. GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, South Africa, China, and Canada. Three trials of its vaccine are in the offing - ...
Regeneron reports positive data for Dupixent pivotal trial. CytoDyn reports encouraging data for Leronlimab in stroke patients. Turning Point Therapeutics announces positive results from TPX-0022 trial. For further details see: Regeneron's Positive Dupixent Data, And Oth...
The Medicines & Healthcare product Regulatory Agency ((MHRA)) of the U.K. government has cleared CytoDyn (CYDY) to file its Biologics License Application ((BLA)) for leronlimab as a combination therapy for multi-drug resistance HIV patients. The clearance included a treatment regimen of o...
VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
CytoDyn (CYDY) announces promising early responses in two patients recovering from strokes.One patient experienced improved sensations in his body and face and the other experienced improvement in her partial paralysis.Chairman, CMO and Head of Business Development Scott Kelly, M.D., says, ...
VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
Dr. Rahman’s 18 years of pharmaceutical industry experience is highlighted by 16 successful BLA/NDAs and sBLAs VANCOUVER, Washington, Oct. 21, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnol...
The independent Data Safety Monitoring Committee ((DSMC)) has completed its first interim analysis of a Phase 2b/3 clinical trial evaluating CytoDyn's (CYDY) leronlimab in severe-to-critical COVID-19 patients. The analysis was performed on data from the first 50% (n=195) of participants.The D...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...